90 -12 (74) 2024 - Khairullayeva G.S. - COVID-19 AND DYSLIPIDEMIA

COVID-19 AND DYSLIPIDEMIA

Khairullayeva G.S. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The COVID‐19 pandemic is a global problem for both the management of patients with acute disease and post-cystic complications. Against the background of COVID-19, the development of systemic inflammation is often observed, accompanied by a "cytokine storm", hemostasis disorders and severe vasculitis. New evidence suggests that impaired regulation of lipid metabolism may contribute to the development of these complications. This review summarizes the latest information on the potential mechanisms associated with dyslipidemia against the background of COVID-19. In particular, it has been suggested that changes in the amount and composition of high-density lipoproteins (HDL) in COVID-19 may significantly weaken the anti-inflammatory and antioxidant effects of HDL and contribute to inflammation in the lungs. In addition, it has been hypothesized that lipoproteins with oxidized phospholipids and fatty acids can lead to viral organ damage due to hyperactivation of scavenger receptors ("scavenger receptors") of innate immunity.

Keywords: COVID-19, dyslipidemia, cytokine storm, vasculitis.

First page

467

Last page

474

For citation:Khairullayeva G.S. - COVID-19 AND DYSLIPIDEMIA//New Day in Medicine 12(74)2024 467-474 https://https://newdayworldmedicine.com/en/new_day_medicine/12-74-2024

List of References

  1. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. //JAMA Intern Med. 2020. https://doi.org/10.1001/jamainternmed.2020.0994. [Epub ahead of print].
  2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. //Lancet. 2020;395(10223):497‐506.
  3. Soares MP, Teixeira L, Moita LF. Disease tolerance and immunity in host protection against infection. //Nat Rev Immunol. 2017;17(2):83‐96.
  4. Libby P, Loscalzo J, Ridker PM, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. //J Am Coll Cardiol. 2018;72(17):2071‐ 2081.
  5. Goeijenbier M, van Sloten TT, Slobbe L, et al. Benefits of flu vaccination for persons with diabetes mellitus: a review. //Vaccine. 2017;35(38):5095‐ 5101.
  6. Desforges JF, Gordon DJ, Rifkind BM. High‐density lipoprotein—the clinical implications of recent studies. //N Engl J Med. 1989;321(19):1311‐1316.
  7. Pencina MJ, D'Agostino RB Sr, Larson MG, Massaro JM, Vasan RS. Predicting the 30‐year risk of cardiovascular disease: the framingham heart study. //Circulation. 2009;119(24):3078‐ 3084.
  8. Acharjee S, Boden WE, Hartigan PM, et al. Low levels of high‐density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post‐hoc analysis from the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation). //J Am Coll Cardiol. 2013;62(20):1826‐1833.
  9. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. //J Lipid Res. 2009;50(suppl):S189‐S194.
  10. Karathanasis SK, Freeman LA, Gordon SM, Remaley AT. The changing face of ЛПВП and the best way to measure it. //Clin Chem. 2017; /63(1):196‐210.
  11. Madsen CM, Varbo A, Nordestgaard BG. Low ЛПВП cholesterol and high risk of autoimmune disease: two population‐based cohort studies including 117341 individuals. //Clin Chem. 2019;65(5):644‐652.
  12. Suzuki M, Pritchard DK, Becker L, et al. High‐density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. //Circulation. 2010;122(19):1919‐1927.
  13. Kabouridis PS, Jury EC. Lipid rafts and T‐lymphocyte function: implications for autoimmunity. //FEBS Lett. 2008;582(27):3711‐3718.
  14. Trinder M, Walley KR, Boyd JH, Brunham LR. Causal inference for genetically determined levels of high‐density lipoprotein cholesterol and risk of infectious disease. //Arterioscler Thromb Vasc Biol. 2020;40(1):267‐278.
  15. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High‐density lipoprotein loses its anti‐inflammatory properties during acute influenza a infection. //Circulation. 2001;103(18):2283‐2288.
  16. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. //J Clin Endocrinol Metab. 1993;76(6):1423‐ 1427.
  17. Xingzhong H, Dong C, Lianpeng W, Guiqing H, Wei Y. Low serum cholesterol level among patients with COVID‐19 infection in Wenzhou, China. Lancet. 2020. http://dx.doi.org/10.2139/ssrn.3544826. [Epub ahead of print].
  18. Fan J, Wang H, Ye G, et al. Letter to the Editor: Low‐density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. //Metabolism. 2020;107:154243.
  19. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. //J Lipid Res. 2004;45(7):1169‐1196.
  20. Han CY, Chiba T, Campbell JS, et al. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A‐I and paraoxonase‐1 by inflammation in murine hepatocytes. //Arterioscler Thromb Vasc Biol. 2006;26(8):1806‐1813.

    file

    download